Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Chest

Volumn 126, Issue 3 SUPPL., 2004, Pages 645S-687S

  Monagle, Paul ^a   Chan, Anthony ^b   Massicotte, Patti ^b   Chalmers, Elizabeth ^b   Michelson, Alan D ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE

Author keywords

Antithrombotic; Child; Heparin; Pediatric; Thromboembolism

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIVITAMIN K; ARGATROBAN; ARGIPRESSIN DERIVATIVE; CLOPIDOGREL; DALTEPARIN; DANAPAROID; DESMOPRESSIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRUDIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTAMINE SULFATE; PROTEIN C; REVIPARIN; STEROID; STREPTOKINASE; TICLOPIDINE; TINZAPARIN; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; AORTA THROMBOSIS; ARTERY CATHETER; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; BONE DENSITY; BRAIN HEMORRHAGE; CALCIFICATION; CHILD CARE; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HUMAN; INTERNATIONAL STANDARD UNIT; LOW DRUG DOSE; META ANALYSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; OSTEOPOROSIS; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; RADIOGRAPHY; REYE SYNDROME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRACHEA DISEASE; UMBILICAL ARTERY CATHETER; VENOUS THROMBOEMBOLISM;

EID: 4644269410     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3_suppl.645S     Document Type: Conference Paper

References (488)

1. Andrew M, Marzinotto V, Brooker LA, et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994; 71:265-269
2. Massicotte P, Marzinotto V, Vegh P, et al. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr 1995; 127:389-394
3. Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 1995; 108(suppl):506S-522S
4. Mitchell L, Abshire T, Hanna K, et al. Supranormalizing antithrombin levels is safe in children with acute lymphoblastic leukemia treated with L-asparaginase: results of the PARKAA study [abstract]. Blood 1999; 94(suppl):27a
5. Massicotte P, Julian J, Gent M, et al. An open label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003; 109:101-108
6. Massicotte P, Julian J, Gent M, et al. An open label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109:85-92
7. Hibbert J, Howlett DC, Greenwood KL, et al. The ultrasound appearances of neonatal renal vein thrombosis. Br J Radiol 1997; 70:1191-1194
8. Cremin BJ, Davey H, Oleszczuk-Raszke K. Neonatal renal venous thrombosis: sequential ultrasonic appearances. Clin Radiol 1991; 44:52-55
9. Wright NB, Blanch G, Walkinshaw S, et al. Antenatal and neonatal renal vein thrombosis: new ultrasonic features with high frequency transducers. Pediatr Radiol 1996; 26:686-689
10. deVeber G, Andrew M. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345:417-423
11. Schmidt B, Andrew M. Neonatal thrombotic disease: prevention, diagnosis, and treatment. J Pediatr 1988; 113:407-410
12. Vailas GN, Brouillette RT, Scott JP, et al. Neonatal aortic thrombosis: recent experience. J Pediatr 1986; 109:101-108
13. Patronas NJ, Duda EE, Mirfakhraee M, et al. Superior sagittal sinus thrombosis diagnosed by computed tomography. Surg Neurol 1981; 15:11-14
14. Gavaert P, Voet D, Achten E, et al. Noninvasive diagnosis of superior sagittal sinus thrombosis in a neonate. Am J Perinatol 1992; 9:201-204
15. Wiznitzer M, Masaryk TJ. Cerebrovascular abnormalities in pediatric stroke: assessment using parenchymal and angiographic magnetic resonance imaging. Ann Neurol 1991; 29:585-589
16. Krishnamoorthy KS, Soman TB, Takeoka M, et al. Diffusion-weighted imaging in neonatal cerebral infarction: clinical utility and follow-up. J Child Neurol 2000; 15:592-602
17. Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002; 87:593-598
18. Chait P, Dinyari M, Massicotte MP. The sensitivity and specificity of lineograms and ultrasound compared to venography for the diagnosis of central venous line related thrombosis in symptomatic children: the LUV study [abstract]. Thromb Haemost 2001; 86(suppl):P697
19. Shankar KR, Abemethy LJ, Das KS, et al. Magnetic resonance venography in assessing venous patency after multiple venous catheters. J Pediatr Surg 2002; 37:175-179
20. Stumper O, Sutherland GR, Geuskens R, et al. Transesophageal echocardiography in evaluation and management after a Fontan procedure. J Am Coll Cardiol 1991; 17:1152-1160
21. Fyfe DA, Kline CH, Sade RM, et al. Transesophageal echocardiography detects thrombus formation not identified by transthoracic echocardiography after the Fontan operation. J Am Coll Cardiol 1991; 18:1733-1737
22. Balling G, Vogt M, Kaemmerer H, et al. Intracardiac thrombus formation after the Fontan operation. J Thorac Cardiovasc Surg 2000; 119:745-752
23. Streif W, Monagle P, South M, et al. Spontaneous arterial thrombosis in children. J Pediatr 1999; 134:110-112
24. Dalen K, Day DL, Ascher NL, et al. Imaging of vascular complications after hepatic transplantation. AJR Am J Roentgenol 1988; 150:1285-1290
25. Kirchhof K, Jansen O, Sartor K. CT angiography of the cerebral veins. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996; 165:232-237
26. Ozsvath RR, Casey SO, Lustrin ES, et al. Cerebral venography: comparison of CT and MR projection venography. AJR Am J Roentgenol 1997; 169:1699-1707
27. Hagen T, Bartylla K, Waziri A, et al. Value of CT angiography in diagnosis of cerebral sinus and venous thrombosis. Radiologe 1996; 36:859-866
28. Tsao PN, Lee WT, Peng SF, et al. Power Doppler ultrasound imaging in neonatal cerebral venous sinus thrombosis. Pediatr Neurol 1999; 21:652-655
29. van Ommen C, Monagle P, Peters M, et al. Pulmonary embolism in childhood. In: van Beek E, Oudkerk M, ten Cate JAV, eds. Pulmonary embolism: epidemiology, diagnosis, and treatment. Oxford, UK: Blackwell Scientific Publishers, 1999; 442-463
30. Newall F, Barnes C, Ignjatovic V, et al. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003; 39:289-292
31. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165-172
32. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12:95-104
33. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651-1657
34. Shah JK, Mitchell LG, Paes B, et al. Thrombin inhibition is impaired in plasma of sick neonates. Pediatr Res 1992; 31:391-395
35. Reverdiau-Moalic P, Delahousse B, Body G, et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88:900-906
36. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114:489S-510S
37. Hirsh J, Dalen J, Anderson D, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114:445S-469S
38. Schmidt B, Ofosu FA, Mitchell L, et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25:405-408
39. Andrew M, Schmidt B, Mitchell L, et al. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990; 63:27-30
40. Andrew M, Mitchell L, Vegh P, et al. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994; 72:836-842
41. Vieira A, Beny L, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991; 63:85-98
42. Chan AK, Berry LR, Monagle PT, et al. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost 2002; 87:606-613
43. Schmidt B, Mitchell L, Ofosu F, et al. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988; 112:641-643
44. Andrew M, Schmidt B. The use of heparin in newborn infants. Semin Thromb Hemost 1988; 14:28-32
45. Andrew M, Ofosu F, Schmidt B, et al. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 1988; 52:517-527
46. Hirsh J. Heparin. N Engl J Med 1991; 324:1565-1574
47. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35:78-83
48. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993; 119:874-881
49. McDonald MM, Jacobson LJ, Hay WW Jr, et al. Heparin clearance in the newborn. Pediatr Res 1981; 15:1015-1018
50. Turner Gomes S, Nitschmann E, et al. Heparin is cleared faster in children with congenital heart disease than adults [abstract]. J Am Coll Cardiol 1993; 21:59a
51. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333-337
52. Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 1975; 52:375-387
53. Schuster J, Meier-Ruge W, Egli F. Pathology of osteopathy following heparin therapy. Dtsch Med Wochenschr 1969; 94:2334-2338
54. Murphy MS, John PR, Mayer AD, et al. Heparin therapy and bone fractures [letter]. Lancet 1992; 340:1098
55. Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radiol 1973; 46:548-550
56. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001; 27:293-299
57. Potter C, Gill JC, Scott JP, et al. Heparin-induced thrombocytopenia in a child. J Pediatr 1992; 121:135-138
58. Klement D, Rammos S, Kries R, et al. Heparin as a cause of thrombus progression: heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996; 155:11-14
59. Murdoch IA, Beattie RM, Silver DM. Heparin-induced thrombocytopenia in children. Acta Paediatr 1993; 82:495-497
60. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70:554-561
61. Schmugge M, Risch L, Huber A, et al. Heparin induced thrombocytopenia associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109:e10
62. Saxon B, Black M, Edgell D, et al. Pediatric heparin induced thrombocytopenia: management with danaparoid (Orgaran). Ann Thorac Surg 1999; 68:1076-1078
63. Severin T, Zieger B, Sutor A. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost 2002; 28:447-454
64. Massicotte MP, Adams M, Leaker M, et al. A nomogram to establish therapeutic levels of the low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolisin (VTE) [abstract]. Thromb Haemost 1997; 78(suppl):282
65. Nohe N, Flemmer A, Rumler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 4 cases. Eur J Pediatr 1999; 158:S134-S139
66. Kuhle S, Massicotte MP, Andrew M, et al. A dose-finding study of tinzaparin in pediatric patients [abstract]. Blood 2002; 100:279a
67. Dunaway KK, Gal P, Ransom JL. Use of enoxaparin in a preterm infant. Ann Pharmacother 2000; 34:1410-1413
68. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439-445
69. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128:313-318
70. Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116:178-186
71. Massonet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16:139-446
72. Harenberg J, Wurzner B, Zimmermann R, et al. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986; 44:549-555
73. Ryn-McKenna J, Cai L, Ofosu FA, et al. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63:271-274
74. Tait DP. Does low molecular weight heparin cause bleeding? Thromb Haemost 1997; 78:1422-1425
75. Haroon Y, Shearer MJ, Rahim S, et al. The content of phylloquinone (vitamin K1) in human milk, cows' milk and infant formula foods determined by high-performance liquid Chromatography. J Nutr 1982; I12:1105-1117
76. Von Kries R, Shearer M, McCarthy PT, et al. Vitamin K1 content of maternal milk: influence of the stage of lactation, lipid composition, and vitamin K1 supplements given to the mother. Pediatr Res 1987; 22:513-517
77. Nowatzke W, Landt M, Smith C, et al. Whole blood international normalization ratio measurements in children using near patient monitors. J Pediatr Hematol Oncol 2003; 25:33-37
78. Massicotte P, Leaker M, Marzinotto V, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998; 80:570-574
79. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94:3007-3014
80. Marzinotto V, Monagle P, Chan A, et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol 2000; 21:347-352
81. Monagle P, Michelson AD, Bovill E, et al. Antithrombotic therapy in children. Chest 2001; 119:344S-370S
82. Taybi H, Capitanio MA. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology 1990; 176:728-730
83. Ries M, Klinge J, Rauch R. Erfahrungen mit der antikoagulatientherapie bei 10 patienten an der Univ Kinderklinik Erlangen. In: Sutor AH, ed. Thrombosen im kindesalter. Basel, Switzerland: Editiones Roche, 1992
84. Massicotte P, Julian J, Webber C, et al. Osteoporosis: a potential complication of long term warfarin therapy [abstract]. Thromb Haemost 1999; 82(suppl):1333a
85. Bolton-Maggs P, Brook L. The use of vitamin K for reversal of over-warfarinization in children. Br J Haematol 2002; 118:924
86. Wilhelm MJ, Schmid C, Kececioglu D, et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996; 61:920-924
87. Rajasekhar D, Kestin AS, Bednarek FJ, et al. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost 1994; 72:957-963
88. Rajasekhar D, Barnard MR, Bednarek FJ, et al. Platelet hyporeactiviry in very low birth weight neonates. Thromb Haemost 1997; 77:1002-1007
89. Ts'ao CH, Green D, Schultz K. Function and ultrastructure of platelets of neonates: enhanced ristocetin aggregation of neonatal platelets. Br J Haematol 1976; 32:225-233
90. Katz JA, Moake JL, McPherson PD, et al. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma. Blood 1989; 73:1851-1858
91. Weinstein MJ, Blanchard R, Moake JL, et al. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1989; 72:68-72
92. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80:1998-2005
93. Sanders J, Holtkamp C, Buchanan GR. The bleeding time may be longer in children than in adults. Am J Pediatr Hematol Oncol 1990; 12:314-318
94. Aversa LA, Vazquez A, Penalver JA, et al. Bleeding time in normal children. J Pediatr Hematol Oncol 1995; 17:25-28
95. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1992; 336:827-830
96. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Doubleblind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340:1421-1425
97. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338:1345-1349
98. Lindblad B, Persson NH, Takolander R, et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993; 24:1125-1128
99. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266
100. Done AK, Yaffe SJ, Clayton JM. Aspirin dosage for infants and children. J Pediatr 1979; 95:617-625
101. McKenzie ME, Gurbel PA, Levine DJ, et al. Clinical utility of available methods for determining platelet function. Cardiology 1999; 92:240-247
102. Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an in vitro platelet function analyzer, PFA-100® Clin Appl Thromb Hemost 1996; 2:241-249
103. Carcao MD, Blanchette VS, Dean JA, et al. The platelet function analyzer (PFA-100): a novel in vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998; 101:70-73
104. Favalaro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100™) with a high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62:165-174
105. Fressinaud E, Veyradier A, Truchand F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91:1325-1331
106. Israels SJ, Cheang T, McMillan-Ward EM, et al. Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer. J Pediatr 2001; 138:116-119
107. Roschitz B, Sudi K, Kostenberger M, et al. Shorter PFA-100 closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor. Acta Paediatr 2001; 90:664-670
108. Porter JD, Robinson PH, Glasgow JF, et al. Trends in the incidence of Reye's syndrome and the use of aspirin. Arch Dis Child 1990; 65:826-829
109. Remington PL, Shabino CL, McGee H, et al. Reye syndrome and juvenile rheumatoid arthritis in Michigan. Am J Dis Child 1985; 139:870-872
110. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83:316-321
111. Starko KM, Ray CG, Dominguez LB, et al. Reye's syndrome and salicylate use. Pediatrics 1980; 66:859-864
112. Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye's syndrome and medication use. JAMA 1982; 248:687-691
113. Young RS, Torretti D, Williams RH, et al. Reye's syndrome associated with long-term aspirin therapy. JAMA 1984; 251:754-756
114. Baum J. Aspirin in the treatment of juvenile arthritis. Am J Med 1983; 74:10-15
115. el Makhlouf A, Friedli B, Oberhansli I, et al. Prosthetic heart valve replacement in children: results and follow-up of 273 patients. J Thorac Cardiovasc Surg 1987; 93:80-85
116. Solymar L, Rao PS, Mardini MK, et al. Prosthetic valves in children and adolescents. Am Heart J 1991; 121:557-568
117. LeBlanc JG, Sett SS, Vince DJ. Antiplatelet therapy in children with left-sided mechanical prostheses. Eur J Cardiothorac Surg 1993; 7:211-215
118. Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitor. Clin Pharm 1992; 11:603-617
119. Savi P, Heilmann E, Nurden P. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost 1996; 2:35-42
120. Herbert JM, Frehl D, Vallee E. Clopidogrel, a novel antiplatelet and antithromhotic agent. Cardiovasc Drug Rev 1993; 11:180-198
121. Lecompte TP, Lecrubier C, Bouloux C. Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers. Clin Appl Thromb Hemost 1997; 3:245-250
122. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation .1995; 92:2373-2380
123. Williams RV, Wilke VM, Tani LY, et al. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002; 109:e4
124. Reverdiau-Moalic P, Gruel Y, Delahousse B, et al. Comparative study of the fibrinolytic system in human fetuses and in pregnant women. Thromb Res 1991; 61:489-499
125. Corrigan JJ Jr., Sleeth JJ, Jeter M, et al. Newborn's fibrinolytic mechanism: components and plasmin generation. Am J Hematol 1989; 32:273-278
126. Bovill EG, Becker R, Tracy R. Monitoring thrombolytic therapy. Prog Cardiovasc Dis 1992; 34:279-294
127. Leaker M, Massicotte MP, Brooker LA, et al. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996; 76:132-134
128. Andrew M, Brooker L, Leaker M, et al. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992; 68:325-330
129. Food and Drug Administration (FDA). Important drug warning regarding the use of Abbokinase (urokinase). Rockville MD: Public Health Service, 1999
130. Browne M, Newall F, Campbell J, et al. Thrombolytic therapy with tissue plasminogen activator (tPA), analysis of safety and outcome in children [abstract]. J Thromb Haemost 2003; 1(suppl):P1488
131. Zenz W, Muntean W, Beitzke A, et al. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children. Br Heart J 1993; 70:382-385
132. Wever ML, Liem KD, Geven WB, et al. Urokinase therapy in neonates with catheter related central venous thrombosis. Thromb Haemost 1995; 73:180-185
133. Gore J, Sloan M, Price T, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study: Thrombolysis in Myocardial Infarction, Phase II, Pilot and Clinical Trial. Circulation 1991; 83:448-459
134. Monagle P, Phelan E, Downie P, et al. Local thrombolytic therapy in children [abstract]. Thromb Haemost 1997; 78:504
135. Kaufman SL, Martin LG, Gilarsky BP, et al. Urokinase thrombolysis using a multiple side hole multilumen infusion catheter. Cardiovasc Intervent Radiol 1991; 14:334-337
136. Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139:682-688
137. Zenz W, Muntean W, Gallistl S, et al. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995; 96:44-48
138. Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1998; 133:137-140
139. Khong PL, John PR. Technical aspects of insertion and removal of an inferior vena cava IVC filter for prophylactic treatment of pulmonary embolus. Pediatr Radiol 1997; 27:239-241
140. McBride WJ, Gadowski GR, Keller MS, et al. Pulmonary embolism in pediatric trauma patients. J Trauma 1994; 37:913-915
141. Williams S, Chait P, Temple M, et al. Vena cava filters in children: review of a single centre clinical experience over 17 years [abstract]. J Thromb Haemost 2003; 90(suppl):OC439
142. Martinez-Ibanez V, Sanchez dT, De Diego M, et al. Wilms' tumours with intracaval involvement. Med Pediatr Oncol 1996; 26:268-271
143. Sarigul A, Farsak B, Koramaz I, et al. Postoperative graft thrombosis in Fontan procedure. Turk J Pediatr 2000; 42:80-83
144. Kokov LS, Korostelev AN, Grinko AN, et al. Recanalization and thrombectomy of internal anastomosis in a patient with tetralogy of Fallot using the AngioJet rheolytic catheter. Catheter Cardiovasc Interv 2001; 53:504-507
145. Ries M, Zenker M, Girisch M, et al. Percutaneous endovascular catheter aspiration thrombectomy of severe superior vena cava syndrome. Arch Dis Child Fetal Neonatal Ed 2002; 87:F64-F66
146. Lodge AJ, Jaggers J, Adams D, et al. Vascular control for resection of suprahepatic intracaval Wilms' tumor: technical considerations. J Pediatr Surg 2000; 35:1836-1837
147. Miletich JP, Prescott SM, White R, et al. Inherited predisposition to thrombosis. Cell 1993; 72:477-480
148. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151:1721-1731
149. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78:297-301
150. Koeleman BP, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-1035
151. Zoller B, Berntsdotter A, Garcia dF, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-3523
152. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75:417-421
153. Nowak-Gottl U, Von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76:F163-F167
154. Debus O, Koch HG, Kurlemann G, et al. Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. Arch Dis Child Fetal Neonatal Ed 1998; 78:F121-F124
155. Nuss R, Hays T, Manco-Johnson M. Childhood thrombosis. Pediatrics 1995; 96:291-294
156. Aschka I, Aumann V, Bergmann F, et al. Prevalence of factor V Leiden in children with thrombo-embolism. Eur J Pediatr 1996; 155:1009-1014
157. Uttenreuther-Fischer MM, Vetter B, Hellmann C, et al. Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Pediatr 1997; 156:277-281
158. Toumi NH, Khaldi F, Ben Becheur S, et al. Thrombosis in congenital deficiencies of AT III, protein C or protein S: a study of 44 children. Hematol Cell Ther 1997; 39:295-299
159. Gurgey A, Mesci L, Renda Y, et al. Factor V Q 506 mutation in children with thrombosis. Am J Hematol 1996; 53:37-39
160. Kohlhase B, Vielhaber H, Kehl HG, et al. Thromboembolism and resistance to activated protein C in children with underlying cardiac disease. J Pediatr 1996; 129:677-679
161. Nowak-Gottl U, Auberger K, Gobel U, et al. Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism. Eur J Pediatr 1996; 155:921-927
162. Vielhaber H, Ehrenforth S, Koch HG, et al. Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. Eur J Pediatr 1998; 157:555-560
163. Nowak-Gottl U, Strater R, Dubbers A, et al. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene. Blood Coagul Fibrinolysis 1996; 7:684-688
164. deVeber G, Monagle P, Chan A, et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998; 55:1539-1543
165. Nuss R, Hays T, Chudgar U, et al. Antiphospholipid antibodies and coagulation regulatory protein abnormalities in children with pulmonary emboli. J Pediatr Hematol Oncol 1997; 19:202-207
166. Uttenreuther-Fischer MM, Ziemer S, Gaedicke G. Resistance to activated protein C (APCR): reference values of APC- ratios for children [letter]. Thromb Haemost 1996; 76:813-814
167. Sifontes MT, Nuss R, Jacobson LJ, et al. Thrombosis in otherwise well children with the factor V Leiden mutation. J Pediatr 1996; 128:324-328
168. Hagstrom JN, Walter J, Bluebond-Langner R, et al. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998; 133:777-781
169. Ganesan V, McShane MA, Liesner R, et al. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998; 65:508-511
170. Bonduel M, Sciuccati G, Hepner M, et al. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch Neurol 1999; 56:967-971
171. Koh S, Chen LS. Protein C and S deficiency in children with ischemic cerebrovascular accident. Pediatr Neurol 1997; 17:319-321
172. Blanco A, Bonduel M, Penalva L, et al. Deep vein thrombosis in a 13-year-old boy with hereditary protein S deficiency and a review of the pediatric literature. Am J Hematol 1994; 45:330-334
173. Zimmerman AA, Watson RS, Williams JK. Protein S deficiency presenting as an acute postoperative arterial thrombosis in a four-year-old child. Anesth Analg 1999; 88:535-537
174. Charuvanij A, Laothamatas J, Torcharus K, et al. Moyamoya disease and protein S deficiency: a case report. Pediatr Neurol 1997; 17:171-173
175. Zoller B, He X, Dahlback B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995; 73:743-745
176. Horowitz IN, Galvis AG, Gomperts ED. Arterial thrombosis and protein S deficiency. J Pediatr 1992; 121:934-937
177. Hauser M, Duque D, Merz U, et al. The clinical outcome after inferior vena cava thrombosis in early infancy. Eur J Pediatr 1999; 158:416-420
178. Pan EY, Gomperts ED, Millen R, et al. Bone mineral density and its association with inherited protein S deficiency. Thromb Res 1990; 58:221-231
179. Michels L. A response to: laboratory testing for thrombophilia in pediatric patients. Thromb Haemost 2002: 88; 155-156
180. Sifontes MT, Nuss R, Hunger SP, et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96:484-489
181. Van ommen C, Heijboer H, Van Den Dool E, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003: 1; 2516-2522
182. Kosch A, Junker R, Kurnik K, et al. prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000: 99; 531-537
183. Young G, Manco-Johnson M, Gill J, et al. Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. J Thromb Haemost 2003: 1; 958-962
184. Fabri D, Belangero VM, Annichino-Bizzacchi JM, et al. Inherited risk factors for thrombophilia in children with nephrotic syndrome. Eur J Pediatr 1998; 157:939-942
185. Seixas CA, Hessel G, Ribeiro CC, et al. Factor V Leiden is not common in children with portal vein thrombosis. Thromb Haemost 1997; 77:258-261
186. Nowak-Gottl U, Koch HG, Aschka I, et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996; 92:992-998
187. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198-202
188. Nowak-Gottl U, Aschka I, Koch HG, et al. Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia: the need for a prospective multicentre study. Blood Coagul Fibrinolysis 1995; 6:761-764
189. Sifontes MT, Nuss R, Hunger SP, et al. Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. Am J Hematol 1998; 57:29-32
190. McColl MD, Chalmers EA, Thomas A, et al. Factor V Leiden, prothrombin 20210G→A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999; 81:690-694
191. Zenz W, Bodo Z, Plotho J, et al. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost 1998; 80:763-766
192. Sutor AH. Screening children with thrombosis for thrombophilic proteins: Cui bono? J Thromb Haemost 2003; 1:886-888
193. Revel-Vilk S, Chan AK, Bauman M, et al. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic events. J Thromb Haemost 2003; 1:915-921
194. Ehrenforth S, Junker R, Koch HG, et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood: Childhood Thrombophilia Study Group. Eur J Pediatr 1999; 158(suppl):S97-S104
195. Mannucci PM, Tripodi A, Bertina RM. Protein S deficiency associated with "juvenile" arterial and venous thromboses [letter]. Thromb Haemost 1986; 55:440
196. Manco-Johnson MJ. Disorders of hemostasis in childhood: risk factors for venous thromboembolism. Thromb Haemost 1997; 78:710-714
197. Andrew M, Michelson AD, Bovill T, et al. The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. J Pediatr Hematol Oncol 1997; 19:7-22
198. Nowak-Gottl U, Schneppenheim R, Vielhaber H. APC resistance in childhood thromboembolism: diagnosis and clinical aspects. Semin Thromb Hemost 1997; 23:253-258
199. Nowak-Gottl U, Dubbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997; 131:608-612
200. Kohlhase B, Kececioglu D, Nowak-Gottl U. Intracardiac thrombus associated with resistance to activated protein C. Cardiol Young 1998; 8:116-118
201. Nowak-Gottl U, Vielhaber H, Schneppenheim R, et al. Coagulation and fibrinolysis in children with APC-resistance: a population based study. Fibrinolysis 1996; 10:25-27
202. Rehan V, Seshia MM. Complications of umbilical vein catheter [letter]. Eur J Pediatr 1994; 153:141
203. Koofman AM, Kootstra G, Zwierstra RP. Portal hypertension in children due to thrombosis of the portal vein. Neth J Surg 1982; 34:97-103
204. Schwartz DS, Gettner PA, Konstantino MM, et al. Umbilical venous catheterization and the risk of portal vein thrombosis. J Pediatr 1997; 131:760-762
205. Brady L, Magilavy D, Black DD. Portal vein thrombosis associated with antiphospholipid antibodies in a child. J Pediatr Gastroenterol Nutr 1996; 23:470-473
206. Arav-Boger R, Reif S, Bujanover Y. Portal vein thrombosis caused by protein C and protein S deficiency associated with cytomegalovirus infection. J Pediatr 1995; 126:586-588
207. Skarsgard E, Doski J, Jaksic T, et al. Thrombosis of the portal venous system after splenectomy for pediatric hematologic disease. J Pediatr Surg 1993; 28:1109-1112
208. Laishram H, Cramer B, Kennedy R. Idiopathic acute portal vein thrombosis: a case report. J Pediatr Surg 1993; 28:1106-1108
209. Arnold KE, Char G, Serjeant GR. Portal vein thrombosis in a child with homoxygous sickle-cell disease. West Indian Med J 1993; 42:27-28
210. Wilson KW, Robinson DC, Hacking PM. Portal hypertension in childhood. Br J Surg 1969; 56:13-22
211. Kowal-Vern A, Radhakrishnan J, Goldman J, et al. Mesenteric and portal vein thrombosis after splenectomy for autoimmune hemolytic anemia. J Clin Gastroenterol 1988; 10:108-110
212. Harper PL, Edgar PF, Luddington RJ, et al. Protein C deficiency and portal thrombosis in liver transplantation in children. Lancet 1988; 2:924-927
213. Macpherson AI. Portal hypertension due to extrahepatic portal venous obstruction; a review of 40 cases. J R Coll Surg Edinb 1984; 29:4-10
214. Pinkerton JA, Holcomb GW Jr., Foster JH. Portal hypertension in childhood. Ann Surg 1972; 175:870-886
215. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96:939-943
216. Chidi CC, King DR, Bales ET Jr. An ultrastructural study of the intimal injury by an indwelling umbilical catheter. J Pediatr Surg 1983; 18:109
217. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978; 12:773-782
218. Pottecher T, Forrler M, Picardat P, et al. Thrombogenicity of central venous catheters: prospective study of polyethylene, silicone and polyurethane catheters with phlebography or post-mortem examination. Eur J Anaesthesiol 1984; 1:361-365
219. Khilnani P, Goldstein B, Todres ID. Double lumen umbilical venous catheters in critically ill neonates: a randomized prospective study. Crit Care Med 1991; 19:1348-1351
220. Storme L, Ouali M, Ganga-Zandzou PS, et al. Use of double-lumen umbilical vein catheters in a neonatal intensive care unit. Arch Pediatr 1999; 6:386-390
221. Yadav S, Dutta AK, Sarin SK. Do umbilical vein catheterization and sepsis lead to portal vein thrombosis? A prospective, clinical, and sonographic evaluation. J Pediatr Gastroenterol Nutr 1993; 17:392-396
222. Tanke RB, van Megen R, Daniels O. Thrombus detection on central venous catheters in the neonatal intensive care unit. Angiology 1994; 45:477-480
223. Roy M, Turner-Gomes S, Gill G. Incidence and diagnosis of neonatal thrombosis associated with umbilical venous catheters [abstract]. Thromb Haemost 1997; 78:724
224. Schmidt B, Zipursky A. Thrombotic disease in newborn infants. Clin Perinatol 1984; 11:461-488
225. Andrew M, Monagle PBL. Epidemiology of venous thromboembolic events: thromboembolic complications during infancy and childhood. Hamilton, ON, Canada: B.C. Decker Inc, 2000; 124
226. Bertrand M, Presant CA, Klein L, et al. Iatrogenic superior vena cava syndrome: a new entity. Cancer 1984; 54:376-378
227. Le Coultre C, Oberhansli I, Mossaz A, et al. Postoperative chylothorax in children: differences between vascular and traumatic origin. J Pediatr Surg 1991; 26:519-523
228. Kramer SS, Taylor GA, Garfinkel DJ, et al. Lethal chylothoraces due to superior vena caval thrombosis in infants. AJR Am J Roentgenol 1981; 137:559-563
229. Kurekci E, Kaye R, Koehler M. Chylothorax and chylopericardium: a complication of a central venous catheter. J Pediatr 1998; 132:1064-1066
230. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83:1251-1257
231. Kuhle S, Koloshuk B, Marzinotto V, et al. A cross sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003; 111:227-233
232. Obladen M, Ernst D, Feist D, et al. Portal hypertension in children following neonatal umbilical disorders. J Perinat Med 1975; 3:101-104
233. Vos LJ, Potocky V, Broker FH, et al. Splenic vein thrombosis with oesophageal varices: a late complication of umbilical vein catheterization. Ann Surg 1974; 180:152-156
234. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47:763-766
235. Adelman RD. Neonatal hypertension. Pediatr Clin North Am 1978; 25:99-110
236. Ling X, Delorme M, Berry L, et al. alpha 2-Macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces. Pediatr Res 1995; 37:373-378
237. Xu L, Delorme M, Berry L, et al. Thrombin generation in newborn and adult plasma in the presence of an endothelial surface [abstract]. Thromb Haemost 1991; 65:1230
238. Nitschmann E, Berry L, Bridge S, et al. Morphological and biochemical features affecting the antithrombotic properties of the aorta in adult rabbits and rabbit pups. Thromb Haemost 1998; 79:1034-1040
239. Carter C, Gent M. The epidemiology of venous thrombosis. In: Colman R, Hirsh J, Marder V, et al, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia, PA: JB Lippincott, 1982; 805-819
240. Perona A, Galligani L. The clinical syndrome associated with antiphospholipid antibodies: a diagnosis to be confirmed after a long follow-up. Minerva Pediatr 1995; 47:39-41
241. Montes de Oca MA, Babron MC, Bletry O, et al. Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch Dis Child 1991; 66:713-717
242. David M, Andrew M. Venous thromboembolic complications in children. J Pediatr 1993; 123:337-346
243. Vain NE, Georgeson KE, Cha CC, et al. Central parenteral alimentation in newborn infants: a new technique for catheter placement. J Pediatr 1978; 93:864-866
244. Warner BW, Gorgone P, Schilling S, et al. Multiple purpose central venous access in infants less than 1,000 grams. J Pediatr Surg 1987; 22:820-822
245. Andrew M, Marzinotto V, Pencharz P, et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 1995; 126:358-363
246. Krafte-Jacobs B, Sivit CJ, Mejia R, et al. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr 1995; 126:50-54
247. Beck C, Dubois J, Grignon A, et al. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 1998; 133:237-241
248. Randolph AG, Cook DJ, Gonzales CA, et al. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 1998; 113:165-171
249. Derish MT, Smith DW, Frankel LR. Venous catheter thrombus formation and pulmonary embolism in children. Pediatr Pulmonol 1995; 20:349-354
250. Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133:770-776
251. Levine M, Hirsh J, Gent M, et al. A randomized trial comparing the activated thromboplastin time with the heparin assay to montor heparin therapy in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154:49-56
252. Tait RC, Ladusans EJ, El Metaal M, et al. Oral anticoagulation in paediatric patients: dose requirements and complications. Arch Dis Child 1996; 74:228-231
253. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30:283-292
254. Andrew M, Monagle P, Brooker L. Thromboembolic complications in specific organ sites and pediatric diseases: thromboembolic complications during infancy and childhood. Hamilton, ON, Canada: B.C. Decker Inc., 2000; 231-276
255. Tinaztepc K, Buyan N, Tinaztepe B, et al. The association of nephrotic syndrome and renal vein thrombosis: a clinicopathological analysis of eight pediatric patients. Turk J Pediatr 1989; 31:1-18
256. Nuss R, Hays T, Manco-Johnson M. Efficacy and safety of heparin anticoagulation for neonatal renal vein thrombosis. Am J Pediatr Hematol Oncol 1994; 16:127-131
257. Trattnig S, Frenzel K, Eilenberger M, et al. Acute renal vein thrombosis in children: early detection with duplex and color-coded Doppler ultrasound. Ultraschall Med 1993; 14:40-43
258. Zigman A, Yazbeck S, Emil S, et al. Renal vein thrombosis: a 10-year review. J Pediatr Surg 2000; 35:1540-1542
259. Mocan H, Beattie TJ, Murphy AV. Renal venous thrombosis in infancy: long-term follow-up. Pediatr Nephrol 1991; 5:45-49
260. Bokenkamp A, Von Kries R, Nowak-Gottl U, et al. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. Eur J Pediatr 2000; 159:44-48
261. Reimold EW, Wittel RA. Renal venous thrombosis in children: changes in management. South Med J 1983; 76:1277-1284
262. Jobin J, O'Regan S, Demay G, et al. Neonatal renal vein thrombosis- long term follow-up after conservative management. Clin Nephrol 1982; 17:36-40
263. Miller RA, Tremann JA, Ansell JS. The conservative management of renal vein thrombosis. J Urol 1974; 111:568-571
264. Belman AB, Susmano DF, Burden JJ, et al. Nonoperative treatment of unilateral renal vein thrombosis in the newborn. JAMA 1970; 211:1165-1168
265. Bromberg WD, Firlit CF. Fibrinolytic therapy for renal vein thrombosis in the child. J Urol 1990; 143:86-88
266. Duncan BW, Adzick NS, Longaker MT, et al. In utero arterial embolism from renal vein thrombosis with successful postnatal thrombolytic therapy. J Pediatr Surg 1991; 26:741-743
267. Vogelzang RL, Moel DI, Cohn RA, et al. Acute renal vein thrombosis: successful treatment with intraarterial urokinase. Radiology 1988; 169:681-682
268. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990; 112:423-428
269. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75:251-253
270. Mismetti P, Mille D, Laporte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003; 88:67-73
271. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21:3665-3675
272. Newall FH, Barnes CB, Savoia HF, et al. Warfarin therapy in children requiring long term total parenteral nurition (TPN). Pediatrics 2003; 112:e386
273. Taussig HB. Long-time observations on the Blalock-Taussig operation IX: single ventricle (with apex to the left). Johns Hopkins Med J 1976; 139:69-76
274. Truccone NJ, Bowman FO Jr., Malm JR, et al. Systemic-pulmonary arterial shunts in the first year of life. Circulation 1974; 49:508-511
275. Tamisier D, Vouhe PR, Vernant F, et al. Modified Blalock-Taussig shunts: results in infants less than 3 months of age. Ann Thorac Surg 1990; 49:797-801
276. Mullen JC, Lemermeyer G, Bentley MJ. Modified Blalock-Taussig shunts: to heparinize or not to heparinize? Can J Cardiol 1996; 12:645-647
277. Tam VK, Murphy K, Parks WJ, et al. Saphenous vein homograft: a superior conduit for the systemic arterial shunt in the Norwood operation. Ann Thorac Surg 2001; 71:1537-1540
278. Bartram U, Grunenfelder J, Van Praagh R. Causes of death after the modified Norwood procedure: a study of 122 postmortem cases. Ann Thorac Surg 1997; 64:1795-1802
279. Pennington DG, Nouri S, Ho J, et al. Glenn shunt: long-term results and current role in congenital heart operations. Ann Thorac Surg 1981; 31:532-539
280. Kopf GS, Laks H, Stansel HC, et al. Thirty-year follow-up of superior vena cava-pulmonary artery (Glenn) shunts. J Thorac Cardiovasc Surg 1990; 100:662-670
281. Koutlas TC, Harrison JK, Bashore TM, et al. Late conduit occlusion after modified Fontan procedure with classic Glenn shunt. Ann Thorac Surg 1996; 62:258-261
282. Monagle P, Karl TR. Thromboembolic problems after the Fontan operation. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002; 5:36-47
283. Monagle P, Cochrane A, McCrindle B, et al. Thromboembolic complications after Fontan procedures: the role of prophylactic: anticoagulation. J Thorac Cardiovasc Surg 1998; 115:493-498
284. Zahn EM, Lima VC, Benson LN, et al. Use of endovascular stents to increase pulmonary blood flow in pulmonary atresia with ventricular septal defect. Am J Cardiol 1992; 70:411-412
285. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348:1639-1646
286. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348:1647-1655
287. Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents: a nationwide study in Finland. Am J Epidemiol 1997; 146:385-393
288. Malcic I, Jelusic M, Kniewald H, et al. Epidemiology of cardiomyopathies in children and adolescents: a retrospective study over the last 10 years. Cardiol Young 2002; 12:253-259
289. Nield LE, McCrindle BW, Bohn DJ, et al. Outcomes for children with cardiomyopathy awaiting transplantation. Cardiol Young 2000; 10:358-366
290. Hsu DT, Addonizio LJ, Hordof AJ, et al. Acute pulmonary embolism in pediatric patients awaiting heart transplantation. J Am Coll Cardiol 1991; 17:1621-1625
291. Baker DW, Wright RF. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994; 272:1614-1618
292. Sade R, Ballenger JF, Hohn A, et al. Cardiac valve replacement in children: Comparison of tissue with mechanical prostheses. J Thorac Cardiovasc Surg 1979; 78:123-127
293. Brown JW, Dunn JM, Spooner E, et al. Late spontaneous disruption of a porcine xenograft mitral valve: clinical, hemodynamic, echocardiographic, and pathological findings. J Thorac Cardiovasc Surg 1978; 75:606-611
294. Geha AS, Laks H, Stansel HC Jr., et al. Late failure of porcine valve heterografts in children. J Thorac Cardiovasc Surg 1979; 78:351-364
295. Silver MM, Pollock J, Silver MD, et al. Calcification in porcine xenograft valves in children. Am J Cardiol 1980; 45:685-689
296. Dunn JM. Porcine valve durability in children. Ann Thorac Surg 1981; 32:357-368
297. Williams WG, Pollack JC, Geiss DM, et al. Experience with aortic and mitral valve replacement in children. J Thorac Cardiovasc Surg 1981; 81:326-333
298. Miller D, Stinson E, Over P, et al. The durability of porcine xenograft valves and conduits in children. Circulation 1982; 66(suppl):1172-1185
299. Odell J. Calcification of porcine bioprostheses in children. In: Cohn L, Gallucci V, eds. Cardiac bioprostheses: proceedings of the second international symposium. New York, NY: Yorke Medical Books, 1982; 231
300. Champsaur G, Robin J, Tronc F, et al. Mechanical valve in aortic position is a valid option in children and adolescents. Eur J Cardiothorac Surg 1997; 11:117-122
301. Yankah AC, Alexi-Meskhishvili V, Weng Y, et al. Performance of aortic and pulmonary homografts in the right ventricular outflow tract in children. J Heart Valve Dis 1995; 4:392-395
302. Freed MD, Keane JF, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation 1974; 50:565-569
303. Freed M, Rosenthal A, Fyler D. Attempts to reduce arterial thrombosis after cardiac catheterization in children: use of percutaneous technique and aspirin. Am Heart J 1974; 87:283-286
304. Rao PS, Thapar MK, Rogers JH Jr., et al. Effect of intraarterial injection of heparin on the complications of percutaneous arterial catheterization in infants and children. Cathet Cardiovasc Diagn 1981; 7:235-246
305. Butt W, Shann F, McDonnell G, et al. Effect of heparin concentration and infusion rate on the patency of arterial catheters. Crit Care Med 1987; 15:230-232
306. Saxena A, Gupta R, Kumar RK, et al. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Cathet Cardiovasc Diagn 1997; 41:400-403
307. Mortensson W, Hallbook T, Lundstrom NR. Percutaneous catheterization of the femoral vessels in children: II. Thrombotic occlusion of the catheterized artery: frequency and causes. Pediatr Radiol 1975; 4:1-9
308. Ino T, Benson LN, Freedom RM, et al. Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am Heart J 1988; 115:633-639
309. Kern IB. Management of children with chronic femoral artery obstruction. J Pediatr Surg 1977; 12:83-90
310. Taylor LM Jr., Troutman R, Feliciano P, et al. Late complications after femoral artery catheterization in children less than five years of age. J Vasc Surg 1990; 11:297-304
311. Celermajer DS, Robinson JT, Taylor JF. Vascular access in previously catheterised children and adolescents: a prospective study of 131 consecutive cases. Br Heart J 1993; 70:554-557
312. Hurwitz RA, Franken EA Jr., Girod DA, et al. Angiographic determination of arterial patency after percutaneous catheterization in infants and small children. Circulation 1977; 56:102-105
313. Girod DA, Hurwitz RA, Caldwell RL. Heparinization for prevention of thrombosis following pediatric percutaneous arterial catheterization. Pediatr Cardiol 1982; 3:175-180
314. Wessel DL, Keane JF, Fellows KE, et al. Fibrinolytic therapy for femoral arterial thrombosis after cardiac catheterization in infants and children. Am J Cardiol 1986; 58:347-351
315. Kirk CR, Qureshi SA. Streptokinase in the management of arterial thrombosis in infancy. Int J Cardiol 1989; 25:15-20
316. Brus F, Witsenburg M, Hofhuis WJ, et al. Streptokinase treatment for femoral artery thrombosis after arterial cardiac catheterisation in infants and children. Br Heart J 1990; 63:291-294
317. Kothari SS, Kumar RK, Varma S, et al. Thrombolytic therapy in infants for femoral artery thrombosis following cardiac catheterisation. Indian Heart J 1996; 48:246-248
318. Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991; 118:467-472
319. Ries M, Singer H, Hofbeck M. Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect. Br Heart J 1994; 72:201-202
320. Lincoln JC, Deverall PB. The treatment of arterial thrombosis in infants and children by balloon catheters. J Pediatr Surg 1969; 4:359-362
321. Mansfield PB, Gazzaniga AB, Litwin SB. Management of arterial injuries related to cardiac catheterization in children and young adults. Circulation 1970; 42:501-507
322. Chaikof EL, Dodson TF, Salam AA, et al. Acute arterial thrombosis in the very young. J Vasc Surg 1992; 16:428-435
323. Sellden H, Nilsson K, Larsson LE, et al. Radial arterial catheters in children and neonates: a prospective study. Grit Care Med 1987; 15:1106-1109
324. Rais-Bahrami K, Karna P, Dolanski EA. Effect of fluids on life span of peripheral arterial lines. Am J Perinatol 1990; 7:122-124
325. Heulitt MJ, Farrington EA, O'Shea TM, et al. Double-blind, randomized, controlled trial of papaverine-containing infusions to prevent failure of arterial catheters in pediatric patients. Grit Care Med 1993; 21:825-829
326. Ritchey ML, Lally KP, Haase GM, et al. Superior mesenteric artery injury during nephrectomy for Wilms' tumor. J Pediatr Surg 1992; 27:612-615
327. Tarry WC, Moser AJ, Makhoul RG. Peripheral arterial thrombosis in the nephrotic syndrome. Surgery 1993; 114:618-623
328. Fletcher MA, Brown DR, Landers S, et al. Umbilical arterial catheter use: report of an audit conducted by the Study Group for Complications of Perinatal Care. Am J Perinatal 1994; 11:94-99
329. Mokrohisky ST, Levine RL, Blumhagen JD, et al. Low positioning of umbilical-artery catheters increases associated complications in newborn infants. N Engl J Med 1978; 299:561-564
330. Harris MS, Little GA. Umbilical artery catheters: high, low, or no. J Perinat Med 1978; 6:15-21
331. Wesstrom G, Finnstrom O, Stenport G. Umbilical artery catheterization in newborns: 1. Thrombosis in relation to catheter type and position. Acta Paediatr Scand 1979; 68:575-581
332. Neal WA, Reynolds JW, Jarvis CW, et al. Umbilical artery catheterization: demonstration of arterial thrombosis by aortography. Pediatrics 1972; 50:6-13
333. Wesstrom G. Umbilical artery catheterization in newborns: V. A clinical follow-up study. Acta Paediatr Scand 1980; 69:371-376
334. Wesstrom G, Lassvik C. Umbilical artery catheterization in newborns: IV. Strain-gauge plethysmography for the diagnosis of catheter-related thrombo-embolism in the legs. Acta Paediatr Scand 1980; 69:365-370
335. Umbilical Artery Catheter Trial Study Group. Relationship of intraventricular hemorrhage or death with the level of umbilical artery catheter placement: a multicenter randomized clinical trial. Pediatrics 1992; 90:881-887
336. Tooley WH, Myerberg DZ. Should we put catheters in the umbilical artery? Pediatrics 1978; 62:853-854
337. Tripp JH, McNinch AW. Haemorrhagic disease and vitamin K (E). Arch Dis Child 1987; 62:436
338. Cochran WD, Davis HT, Smith CA. Advantages and complications of umbilical artery catheterization in the newborn. Pediatrics 1968; 42:769-777
339. Gilhooly J, Lindberg J, Reynolds J. Survey of umbilical artery catheter practices. Clin Res 1986; 34:142-143
340. Kempley ST, Bennett S, Loftus BG, et al. Randomized trial of umbilical arterial catheter position: clinical outcome. Acta Paediatr 1993; 82:173-176
341. Krueger TC, Neblett WW, O'Neill JA, et al. Management of aortic thrombosis secondary to umbilical artery catheters in neonates. J Pediatr Surg 1985; 20:328-332
342. Stringel G, Mercer S, Richler M, et al. Catheterization of the umbilical artery in neonates: surgical implications. Can J Surg 1985; 28:143-146
343. Malloy MH, Cutter GR. The association of heparin exposure with intraventricular hemorrhage among very low birth weight infants. J Perinatol 1995; 15:185-191
344. Bryant BG. Drug, fluid, and blood products administered through the umbilical artery catheter: complication experiences from one NICU. Neonatal Netw 1990; 9:27-32, 43-46
345. Martin JE Jr., Moran JF, Cook LS, et al. Neonatal aortic thrombosis complicating umbilical artery Catheterization: successful treatment with retroperitoneal aortic thrombectomy. Surgery 1989; 105:793-706
346. Alpert J, O'Donnell JA, Parsonnet V, et al. Clinically recognized limb ischemia in the neonate after umbilical artery catheterization. Am J Surg 1980; 140:413-418
347. O'Neill JA Jr., Neblett WW III, Boni ML. Management of major thromboembolic complications of umbilical artery catheters. J Pediatr Surg 1981; 16:972-978
348. Caeton AJ, Goetzman BW. Risky business: umbilical arterial catheterization. Am J Dis Child 1985; 139:120-121
349. Cohen RS, Ramachandran P, Kim EH, et al. Retrospective analysis of risks associated with an umbilical artery catheter system for continuous monitoring of arterial oxygen tension. J Perinatol 1995; 15:195-198
350. Jackson JC, Truog WE, Watchko JF, et al. Efficacy of thromboresistant umbilical artery catheters in reducing aortic thrombosis and related complications. J Pediatr 1987; 110:102-105
351. Tooley WH. What is the risk of an umbilical artery catheter? Pediatrics 1972; 50:1-2
352. Joseph R, Chong A, Teh M, et al. Thrombotic complication of umbilical arterial catheterization and its sequelae. Ann Acad Med Singapore 1985; 14:576-582
353. Rajani K, Goetzman BW, Wennberg RP, et al. Effect of heparinization of fluids infused through an umbilical artery catheter on catheter patency and frequency of complications. Pediatrics 1979; 63:552-556
354. Bejar R, Curbelo V, Coen RW, et al. Diagnosis and follow-up of intraventricular and intracerebral hemorrhages by ultrasound studies of infant's brain through the fontanelles and sutures. Pediatrics 1980; 66:661-673
355. Bosque E, Weaver L. Continuous versus intermittent heparin infusion of umbilical arteiy catheters in the newborn infant. J Pediatr 1986; 108:141-143
356. Horgan MJ, Bartoletti A, Polansky S, et al. Effect of heparin infusates in umbilical arterial catheters on frequency of thrombotic complications. J Pediatr 1987; 111:774-778
357. Ankola PA, Atakent YS. Effect of adding heparin in very low concentration to the infusate to prolong the patency of umbilical artery catheters. Am J Perinatol 1993; 10:229-232
358. David RJ, Merten DF, Anderson JC, et al. Prevention of umbilical artery catheter clots with heparinized infusates. Dev Pharmacol Ther 1981; 2:117-126
359. Chang GY, Lueder FL, DiMichele DM, et al. Heparin and the risk of intraventricular hemorrhage in premature infants. J Pediatr 1997; 131:362-366
360. Lesko SM, Mitchell AA, Epstein MF, et al. Heparin use as a risk factor for intraventricular hemorrhage in low- birth-weight infants. N Engl J Med 1986; 314:1156-1160
361. Oates-Whitehead R, Baumer J, Haines L, et al. Intravenous immunoglobulin for the treatemnt of Kawasaki's disease in children. Cochrane Database Syst Rev (database online). Issue 4, 2003
362. Di Bernardo S, Sekarski N, Tolsa JF, et al. Subtotal thrombosis of the juxta-ductal thoracic aorta in a premature 36-week-old infant: alteplase therapy. Arch Mal Coeur Vaiss 1999; 92:661-665
363. Suri M, Ramji S, Thirnpuram S, et al. Spontaneous aortic thrombosis in a neonate. Indian Pediatr 1994; 31:846-849
364. Kawahira Y, Kishimoto H, Lio M. Spontaneous aortic thrombosis in a neonate with multiple thrombi in the main branches of the abdominal aorta. Cardiovasc Surg 1995; 3:291-321
365. Munoz-Arizpe R, Walsh RF, Edge W. Obstructive aortic and renal thrombosis in the newborn-spontaneous recovery. Pediatr Nephrol 1992; 6:190-191
366. Hamilton RM, Penkoske PA, Byrne P, et al. Spontaneous aortic thrombosis in a neonate presenting as coarctation. Ann Thorac Surg 1988; 45:564-565
367. Shennan GG, Munster M, Govendrageloo K, et al. Low molecular weight heparin in the successful treatment of a spontaneous aortic thrombosis in a neonate. Pediatr Hematol Oncol 2000; 17:409-413
368. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96:1057-1061
369. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055-1058
370. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-347
371. Towbin A. Central nervous system damage in the human fetus and newborn infant: mechanical and hypoxic injury incurred in the fetal-neonatal period. Ann J Dis Child 1970; 119:529-542
372. Barron TF, Gusnard DA, Zimmerman RA, et al. Cerebral venous thrombosis in neonates and children. Pediatr Neurol 1992; 8:112-116
373. Newton TH, Gooding CA. Compression of superior sagittal sinus by neonatal Calvarial molding. Neuroradiology 1975; 115:635-639
374. Cowan F, Thoresen M. Changes in superior sagittal sinus blood velocities sue to postural alterations and pressure on the head of the newborn infant. Pediatrics 1985; 75:1038-1047
375. Lee BC, Voorhies TM, Ehrlich ME, et al. Digital intravenous cerebral angiography in neonates. AJNR Am J Neuroradiol 1984; 5:281-286
376. deVeber GA, MacGregor D, Curtis R, et al. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000; 15:316-324
377. Khurana DS, Buonanno F, Ebb D, et al. The role of antieoagulation in idiopathic cerebral venous thrombosis. J Child Neurol 1996; 11:248-250
378. Samuel J, Fernandes CMC. Lateral sinus thrombosis (a review of 45 cases). J Laryngol Otol 1987; 101:1227-1229
379. Leker RR, Steiner I. Features of dural sinus thrombosis simulating pseudotumor cerebri. Eur J Neurol 1999; 6:001-604
380. Bousser MG, Russell RR. Cerebral venous thrombosis. Toronto, ON, Canada: WB Saumlers, 1997
381. Cantu C, Barinagarrementeria F. Cerebral venous thrombosis associated with pregnancy and puerperium: review of 67 cases. Stroke 1993; 24:1880-1884
382. Brown MT, Friedman HS, Oakes WJ, et al. Sagittal sinus thrombosis and leptomeningeal medulloblastoma. Neurology 1991; 41:455-456
383. Hickey WF, Garnick MB, Henderson IC, et al. Primary cerebral venous thrombosis in patients with cancer: a rarely diagnosed paraneoplastic syndrome; report of three cases and review of the literature. Am J Med 1982; 73:740-750
384. Dindar F, Platts ME. Intracranial venous thrombosis complicating oral contraception. Can Med Assoc J 1974; 11:545-548
385. Lin CC, Lui CC, Tain YL. Thalamic stroke secondary to straight sinus thrombosis in a nephrotic child. Pediatr Nephrol 2002; 17:184-186
386. Keane S, Gallagher A, Ackroyd S, et al. Cerebral venous thrombosis during diabetic ketoacidosis. Arch Dis Child 2002; 86:204-205
387. Hartfield DS, Lowry NJ, Keene DL, et al. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol 1997; 16:50-53
388. Visudtibhan A, Visudhiphan P, Chiemchanya S. Cavernous sinus thrombophlebitis in children. Pediatr Neurol 2001; 24:123-127
389. Ali SM, Ahmed SH. Cavernous sinus thrombosis in children, J Trop Pediatr 1992; 38:194-195
390. de Bruijn SF, Stain J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30:484-488
391. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338:597-600
392. Stain J, de Bruijn SFTM, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev (database online). Issue 3, 2004
393. Lynch JK, Hirtz, DG, deVeber G, et al. Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics 2002; 109:116-123
394. Estan J, Hope P. Unilateral neonatal cerebral infarction in full term infants. Arch Dis Child Fetal Neonatal Ed 1997; 76:F88-F93
395. Levy SR, Abroms IF, Marshall PC, et al. Seizures and cerebral infarction in the full-term newborn. Ann Neurol 1985; 17:366-370
396. deVeber G, The Canadian Pediatric Ischemic Stroke Study Group. Canadian paediatric ischemic stroke registry: analysis of children with arterial ischemic stroke [abstract]. Ann Neurol 2000; 48:526
397. Kerr LM, Anderson DM, Thompson JA, et al. Ischemic stroke in the young: evaluation and age comparison of patients six months to thirty-nine years. J Child Neurol 1993; 8:266-270
398. Rich C, Gill JC, Wernick S, et al. An unusual cause of cerebral venous thrombosis in a four-year-old child. Stroke 1903; 24:603-605
399. Ganesan V, Kelsey H, Cookson J, et al. Activated protein C resistance in childhood stroke [letter]. Lancet 1996; 347:260
400. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke: a selective review. Stroke 1990; 21:1111-1121
401. Gobel U. Inherited or acquired disorders of blood coagulation in children with neurovascular complications. Neuropediatrics 1994; 25:4-7
402. Vomberg PP, Breederveld C, Fleury P, et al. Cerebral thromboembolism due to antithrombin III deficiency in two children. Neuropediatrics 1987;18:42-44
403. Nowak-Gottl U, Junker R, Hartmeier M, et al. Increased lipoprotein(a) is an important risk factor for venons thromboembolism in childhood. Circulation 1999; 100:743-748
404. Nowak-gottl U, Schobess R, Kurnik K, et al. Elevated lipoprotein(a) concentration is an independent risk factor of venous thromboembolism. Blood 2002; 99:3476-3477
405. Ebert W, Schneppenheim R. Perinatal stroke in 4 newborns with FV Leiden [abstract]. Thromb Haemost 1997; 78(suppl):PS-410
406. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venons thrombosis. Blood 1996; 88:3698-3703
407. Roddy SM, Giang DW. Antiphospholipid antibodies and stroke in an infant. Pediatrics 1991; 87:933-935
408. de Klerk OL, de Vries TW, Sinnige LG. An unusual cause of neonatal seizures in a newborn infant. Pediatrics 1997; 100:e8
409. deVeber G, Adams M, Andrew M. Canadian Pediatric Ischemic Stroke Registry (Analysis III). Can J Neurol Sci 1995;22(suppl):S24
410. Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry 1985; 48:650-657
411. Perlman J, Rollins N, Evans D, Neonatal stroke: clinical characteristics and cerebral blood flow velocity measurements. Pediatr Neurol 1994; 11:281-284
412. Colomb M, Macgregor D, Doini T, et al, presumed pre or perinatal arterial ischaemic stroke: risk factors and outcomes. Ann Neurol 2001; 50:163-168
413. Andrew M, Monagle P, deVeber G, et al. Thromboembolic disease and antithrombotic therapy in newborns. Hematology (Am Soc Hematol Educ Program) 2001; 358-374
414. Kurnik K, Kosch A, Strater R, et al. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke; a prospective follow up study. Stroke 2003; 34:2887-2892
415. Albers GW, Easton JD, Sacco RL, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114:683S-698S
416. Schoenberg B, Mellinger J, Sehoenberg D. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. Neurology 1978; 28:763-768
417. Broderick J, Talhot GT, Prenger E, et al. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. J Child Neurol 1993; 8:250-255
418. Yang JS, Park YD, Hartlage PL. Seizures associated with stroke in childhood. Pediatr Neurol 1995; 12:136-138
419. Trescher WH. Ischemic stroke syndromes in childhood. Pediatr Ann 1992; 21:374-383
420. Demierre B, Rondot P. Dystonia caused by putamino-capsulo-caudate vascular lesions. J Neurol Neurosurg Psychiatry 1983; 46:404-409
421. deVeber G and Andrew M. Canadian Pediatric Ischemic Stroke Registry: analysis I [abstract]. Pediatr Res 1994; 35:379A
422. deVeber G, Adams M, Andrew M. Neonatal cerebral thromboembolism: clinical and radiographic features [abstract]. Thromb Haemost 1997; 78(suppl):725
423. Ball WS. Cerebrovascular occlusive disease in childhood. Neuroimaging Clin N Am 1994; 4:393-421
424. Martin PJ, Enevoldson TP, Humphrey PR. Causes of ischaemie stroke in the young. Postgrad Med J 1997; 73:8-16
425. Suzuki J, Kodama N. Moyamoya disease: a review. Stroke 1983; 14:104-109
426. Golden G. Cerebrovascular disease. In: Swaiman K, ed. Pediatric neurologie diseases. St. Louis, MO: Mosby, 1989; 603-617
427. Maki Y, Nakada Y, Nose T, et al. Clinical and radioisotopic follow-up study of "Moyamoya". Childs Brain 1976; 2:257-271
428. Yoshida S, Yamamoto T, Yoshioka M, et al. Ischemic stroke in childhood. No Shinkei Geka 1993; 21:611-616
429. deVeber G. Cerebrovascular diseases in children. In: Swaiman KF, Ashwal S, eds. Pediatric neurology: principles and practice. St Louis, MO: Mosby, 1999; 1099-1124
430. Andrew M, deVeber G. Pediatric thromboembolism and stroke protocols. Hamilton, ON, Canada: B.C. Decker Inc, 1999
431. Earley CJ, Kittner SJ, Feeser BR, et al. Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. Neurology 1998; 51:169-176
432. Powars DR, Conti PS, Wong WY, et al. Cerebral vasculopathy in sickle cell anemia: diagnostic contribution of positron emission tomography. Blood 1999; 93:71-79
433. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis; The Cooperative Study of Sickle Cell Disease. Pediatrics 1999; 103:640-645
434. Reed W, Jagust W, Al Mateen M, et al. Role of positron emission tomography in determining the extent of CNS ischemia in patients with sickle cell disease. Am J Hematol 1999; 60:268-272
435. Liesner R, Mackie I, Cookson J, et al. Prothrombotic changes in children with sickle cell disease: relationships to Cerebrovascular disease and transfusion. Br J Haematol 1998; 103:1037-1044
436. Adams RJ, Nichols F. Sickle cell anemia, sickle cell trait and thalassemia. In: Vinken P, Bruyn GW, Klawans H, eds. Vascular diseases III: handbook of clinical neurology. New York, NY: Elsevier Scientific Publications, 1988; 503-515
437. Williams LS, Grag BP, Cohen M, et al. Subtypes of ischemic stroke in children and young adults. Neurology 1997; 49:1541-1545
438. Wolters HJ, ten Gate H, Thomas LL, et al. Low-intensity oral anticoagulation in sickle-cell disease reverses die prethrombotic state: promises for treatment? Br J Haematol 1995; 90:715-717
439. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk-factors. Blood 1998; 91:288-294
440. National Institutes of Health. Stroke and central nervous system disease: the management of sickle cell disease. Bethesda, MD; National Institute of Health, 2002; Publication No. 02-2117
441. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997; 42:699-704
442. Pescatore P, Horellou HM, Conard J, et al. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb Haemost 1993; 69:311-315
443. Marlar RA, Sills RH, Groncy PK, et al. Protein C survival during replacement therapy in homozygous protein C deficiency. Am J Hematol 1992; 41:24-31
444. Deguchi K, Tsukada T, Iwasaki E, et al. Late-onset homozygous protein C deficiency manifesting cerebral infarction as the first symptom at age 27. Intern Med 1992; 31:922-925
445. Yamamoto K, Matsushita T, Sugiura I, et al. Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. J Lab Clin Med 1992; 119:682-689
446. Auberger K. Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann Hematol 1992; 64:146-151
447. Grundy CB, Melissari E, Lindo V, et al. Late-onset homozygous protein C deficiency. Lancet 1991; 338:575-576
448. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16:299-309
449. Tripodi A, Franchi F, Krachmalnicoff A, et al. Asymptomatic homozygous protein C deficiency. Acta Haematol 1990; 83:152-155
450. Petrini P, Segnestam K, Ekelund H, et al. Homozygous protein C deficiency in two siblings. Pediatr Hematol Oncol 1990; 7:165-175
451. Marlar RA, Adcock DM, Madden RM. Hereditary dysfunctional protein C molecules (type II): assay characterization and proposed classification. Thromb Haemost 1990; 63:375-379
452. Marlar RA, Montgomery RR, Broekmans AW. Report on the diagnosis and treatment of homozygous protein C deficiency: report of the Working Party on Homozygous Protein C Deficiency of the ICTH-Subcommittee on Protein C and Protein S. Thromb Haemost 1989; 61:529-531
453. Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61:50-54
454. Tuddenham EG, Takase T, Thomas AE, et al. Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. Thromb Res 1989; 53:475-484
455. Vukovich T, Auberger K, Weil J, et al. Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S. Br J Haematol 1988; 70:435-440
456. Gladson CL, Groncy P, Griffin JH. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency. Arch Dermatol 1987; 123;1701a-1706a
457. Peters C, Casella JF, Marlar RA, et al. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics 1988; 81:272-276
458. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991-996
459. Rappaport ES, Speights VO, Helbert B, et al. Protein C deficiency. South Med J 1987; 80:240-242
460. Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency: report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 1989; 114:528-534
461. Pegelow CH, Curless R, Bradford B. Severe protein C deficiency in a newborn. Am J Pediatr Hematol Oncol 1988; 10:326-329
462. Gomez E, Ledford MR, Pegelow CH, et al. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994; 71:723-726
463. Mahasandana C, Suvatte V, Chuansumrit A, et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117:750-753
464. Mahasandana C, Suvatte V, Marlar RA, et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335:61-62
465. Hui CH, Lam CC, Sze CS. A family of protein S deficiency including two adults with homozygous deficiency. Thromb Haemost 1997; 78:1158-1159
466. Mahasandana C, Veerakul G, Tanphaichitr VS, et al. Homozygous protein S deficiency: 7-year follow-up [letter]. Thromb Haemost 1996; 76:1122
467. Mintz-Hittner HA, Miyashiro MJ, Knight-Nanan DM, et al. Vitreoretinal findings similar to retinopathy of prematurity in infants with compound heterozygous protein S deficiency. Ophthalmology 1999; 106:1525-1530
468. Pung-Amritt P, Poort SR, Vos HL, et al. Compound heterozygosity for one novel and one recurrent mutation in a Thai patient with severe protein S deficiency. Thromb Haemost 1999; 81:189-192
469. Burrows RF, Kelton J. Low fetal risks in pregnancies associated with idiopathic thrombocytopenic purpura do not justify obstetrical interventions. Am J Obstet Gynecol 1990; 163:1147-1150
470. Adcock DM, Brozna J, Marlar RA. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis. Semin Thromb Hemost 1990; 16:333-340
471. Auletta MJ, Headington JT. Purpura fulminans: a cutaneous manifestation of severe protein C deficiency. Arch Dermatol 1988; 124:1387-1391
472. Adcock DM, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminans. Semin Thromb Hemost 1990; 16:283-292
473. Estelles A, Garcia-Plaza I, Dasi A, et al. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost 1984; 52:53-56
474. Sade RM, Crawford FA Jr., Fyfe DA, Stroud MR. Valve prostheses in children: a reassessment of anticoagulation. J Thorac Cardiovasc Surg 1988; 95:553-561
475. Serra AJ, McNicholas KW, Olivner HF Jr., et al. The choice of anticoagulation in pediatric patients with the St. Jude Medical valve prostheses. J Cardiovasc Surg (Torino) 1987; 28:588-591
476. McGrath LB, Gonzalez-Lavin L, Eldredge WJ, et al. Thromboembolic and other events following valve replacement in a pediatric population treated with antiplatelet agents. Ann Thorac Surg 1987; 43:285-287
477. Bradley LM, Midgley FM, Watson DC, et al. Anticoagulation therapy in children with mechanical prosthetic cardiac valves. Am J Cardiol 1985; 56:533-535
478. Borkon AM, Soule L, Reitz BA, et al. Five year follow-up after valve replacement with the St. Jude Medical valve in infants and children. Circulation 1986; 74:1110-1115
479. Bradley SM, Sade RM, Crawford FA Jr., et al. Anticoagulation in children with mechanical valve prostheses. Ann Thorac Surg 1997; 64:30-34
480. Spevak PJ, Freed MD, Castaneda AR, et al. Valve replacement in children less than 5 years of age. J Am Coll Cardiol 1986; 8:901-908
481. Harada Y, Imai Y, Kurosawa H, et al. Ten-year follow-up after valve replacement with the St. Jude Medical prosthesis in children. J Thorac Cardiovasc Surg 1990; 100:175-180
482. Stewart S, Cianciotta D, Alexson C, et al. The long-term risk of warfarin sodium therapy and the incidence of thromboembolism in children after prosthetic cardiac valve replacement. J Thorac Cardiovasc Surg 1987; 93:551-554
483. Milano A, Vouhe PR, Baillot-Vernant F, et al. Late results after left-sided cardiac valve replacement in children. J Thorac Cardiovasc Surg 1986; 92:218-225
484. Schaffer MS, Clarke DR, Campbell DN, et al. The St. Jude Medical cardiac valve in infants and children: role of anticoagulant therapy. J Am Coll Cardiol 1987; 9:235-239
485. Schaff HV, Danielson GK, DiDonato RM, et al. Late results after Starr-Edwards valve replacement in children. J Thorac Cardiovasc Surg 1984; 88:583-589
486. Human DG, Joffe HS, Fraser CB, et al. Mitral valve replacement in children. J Thorac Cardiovasc Surg 1982; 83:873-877
487. Antunes MJ, Vanderdonck KM, Sussman MJ. Mechanical valve replacement in children and teenagers. Eur J Cardiothorac Surg 1989; 3:222-228
488. Woods A, Vargas J, Berri G, et al. Antithrombotic therapy in children and adolescents. Thromb Res 1986; 42:289-301